BCYC Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $3.38
Market Cap (MRQ) $236M
P/E (TTM) -1.2
EPS (TTM) $-2.73
Revenue (TTM) $61M
ROE (TTM) -32.3%
52W Range $3–$9

BCYC Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

About Bicycle Therapeutics plc - American Depositary Shares Company overview from Wikipedia

05 · wikidata
sectorHealthcare industryBiotechnology employees288 countryGB

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$73M
2017-12-31 → 2025-12-31
EPS$-3.16
2019-12-31 → 2025-12-31
Free Cash Flow$-252M
2019-12-31 → 2025-12-31
Net margin-311.1%
2019-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend BCYC 5Y avg Peer Median Verdict
P/E (TTM) -1.25Y avg ≈-8.2 ≈-8.2 · ·
P/S (TTM) 3.95Y avg ≈55.5 ≈55.5 · ·
P/B (MRQ) 0.55Y avg ≈2.5 ≈2.5 · ·
Price / FCF (TTM) -1.15Y avg ≈-27.1 ≈-27.1 · ·
Price / Cash Flow (TTM) -1.15Y avg ≈-30.5 ≈-30.5 · ·
Price / Tangible Book 0.45Y avg ≈2.5 ≈2.5 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 2.7%
Next Report Oct 28, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 6, 2026 $-0.72 $-0.59 -22.6%
March 31, 2026 $-0.87 $-0.63 -37.4%
Dec. 31, 2025 $-0.29 $-0.96 69.7%
Sept. 30, 2025 $-0.85 $-1.10 22.7%
June 30, 2025 $-1.14 $-0.97 -17.5%
March 31, 2025 $-0.88 $-0.86 -2.4%
Dec. 31, 2024 $-0.82 $-0.88 6.4%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 15
Metric Trend 20252024202320222021202020192018
Revenue $73M$35M$27M$14M$12M$10M$14M$7M
R&D Expense $240M$173M$156M$82M$45M$33M$26M$21M
SG&A Expense $79M$72M$60M$50M$32M$29M$15M$8M
Operating Expenses $320M$245M$217M$131M$77M$62M$40M$29M
Operating Income $-247M$-210M$-190M$-117M$-66M$-52M$-26M$-22M
Interest Expense ··$3M$3M$3M$457.0K··
Other Non-op $28M$36M$11M$2M$-3M$226.0K$-5M$-665.0K
Pretax Income $-219M$-174M$-179M$-114M$-68M$-52M$-31M$-22M
Income Tax $152.0K$-5M$1M$-2M$-2M$-724.0K$-254.0K$-396.0K
Net Income $-219M$-169M$-181M$-113M$-67M$-51M$-31M$-22M
EPS (Basic) $-3.16$-2.90$-5.08$-3.80$-2.67$-2.66$-2.77·
EPS (Diluted) $-3.16$-2.90$-5.08$-3.80$-2.67$-2.66$-2.77·
Shares (Basic) 69,279,83858,207,59335,592,36229,660,65925,061,73419,145,93811,045,370·
Shares (Diluted) 69,279,83858,207,59335,592,36229,660,65925,061,73419,145,93811,045,370·
EBITDA $-241M$-203M$-183M$-113M$-64M$-51M$-25M·
Balance Sheet 24
Metric Trend 20252024202320222021202020192018
Cash & Equivalents $628M$880M$526M$339M$439M$136M$0$0
Receivables $0$0$0$2M$1M$5M$201.0K$5M
Prepaid Expense $19M$13M$11M$9M$8M$5M$5M$2M
Current Assets $683M$929M$562M$369M$459M$156M$104M$77M
PP&E (Net) $6M$10M$15M$19M$3M$2M$2M$2M
PP&E (Gross) ··$28M$27M$8M$6M$5M$4M
Accum. Depreciation ··$13M$8M$5M$4M$3M$2M
Other Non-current Assets $13M$11M$6M$8M$3M$2M$2M$3M
Total Assets $718M$957M$595M$411M$480M$161M$110M$82M
Accounts Payable $10M$16M$13M$6M$3M$1M$2M$2M
Accrued Liabilities $44M$41M$32M$26M$14M$12M$6M$7M
Current Liabilities $57M$67M$70M$53M$36M$23M$9M$9M
Capital Leases $14M$4M$9M$11M$12M$426.0K$1M·
Other Non-current Liabilities $1M$1M$5M$4M$3M$3M$2M$897.0K
Total Liabilities $108M$164M$224M$140M$134M$66M$17M$29M
Long-term Debt ··$31M$30M$30M$15M··
Total Debt ··$31M$30M$30M$15M··
Common Stock $894.0K$890.0K$550.0K$387.0K$384.0K$266.0K$227.0K$10.0K
Paid-in Capital $1.51B$1.47B$883M$601M$568M$250M$195M$2M
Retained Earnings $-900M$-681M$-512M$-331M$-218M$-152M$-101M$-70M
AOCI $-4M$119.0K$-1M$387.0K$-3M$-3M$-2M$-2M
Stockholders' Equity $610M$793M$371M$271M$346M$95M$93M$-70M
Liabilities + Equity $718M$957M$595M$411M$480M$161M$110M$82M
Shares Outstanding 69,367,89669,061,41842,431,76629,873,89329,579,36421,094,55717,993,701814,728
Cash Flow 16
Metric Trend 20252024202320222021202020192018
D&A $6M$7M$7M$4M$1M$1M$960.0K$712.0K
Stock-based Comp $39M$38M$32M$27M$12M$7M$3M$1M
Deferred Tax $-850.0K$-5M$3M$-5M$-2M$-673.0K$-364.0K$-378.0K
Restructuring ·$2M······
Other Non-cash $-76M$-36M$78M$1M$40M$26M$-2M·
Operating Cash Flow $-250M$-165M$-61M$-86M$-15M$-18M$-29M$-26M
CapEx $2M$1M$3M$19M$2M$1M$2M$1M
Investing Cash Flow $-2M$-1M$-3M$-19M$-2M$-1M$-2M$-1M
Net Debt Issued ·$-32M······
Stock Issued ·$544M$249M$6M$291M$48M··
Net Stock Activity ·$544M$249M$6M$8M···
Financing Cash Flow $-131.0K$520M$250M$7M$321M$63M$58M$25M
Net Change in Cash $-251M$353M$188M$-100M$303M$44M$29M$-4M
Taxes Paid $-717.0K$792.0K$562.0K$2M$73.0K$124.0K$117.0K$73.0K
Free Cash Flow $-252M$-166M$-64M$-105M$-17M$-19M$-30M·
Levered FCF ··$-67M$-108M$-20M$-19M··
Profitability 7
Metric Trend 20252024202320222021202020192018
Operating Margin -340.4%-595.0%-704.1%-806.6%-561.0%-500.1%-190.6%·
Net Margin -301.7%-479.2%-669.7%-779.4%-571.2%-490.9%-221.8%·
Pretax Margin -301.4%-492.7%-664.3%-789.9%-585.5%-497.9%-223.6%·
EBITDA Margin -331.5%-574.6%-679.9%-781.1%-548.9%-487.8%-183.6%·
ROA -26.2%-21.8%-35.9%-25.3%-20.8%-37.6%-31.9%·
ROE -34.2%-20.8%-45.9%-40.2%-25.8%-49.8%-32.5%·
ROIC -40.5%-25.7%-47.7%-38.2%-17.0%-46.6%-28.0%·
Liquidity & Solvency 5
Metric Trend 20252024202320222021202020192018
Current Ratio 12.013.88.16.912.76.711.8·
Quick Ratio 11.013.17.66.412.10.20.0·
Debt / Equity ··0.10.10.10.2··
LT Debt / Equity ··0.10.10.10.2··
Interest Coverage ··-58.2-34.9-22.0-113.7··
Efficiency 2
Metric Trend 20252024202320222021202020192018
Asset Turnover 0.10.00.10.00.00.10.1·
Receivables Turnover ··26.49.53.63.75.3·
Per Share 6
Metric Trend 20252024202320222021202020192018
Book Value / Share $8.79$11.48$8.74$9.06$11.71$4.53$5.18·
Revenue / Share $1.05$0.61$0.76$0.49$0.47···
Cash Flow / Share $-3.60$-2.83$-1.70$-2.90$-0.59···
Cash / Share $9.05$12.74$12.41$11.35$14.83$0.00$0.00·
Dividend / Share $0.00$0.00$0.00$0.00$0.00···
EPS (TTM) $-3.16$-2.90$-5.08$-3.80$-2.67$-2.66$-2.77·
Growth Rates 3
Metric Trend 20252024202320222021202020192018
Revenue YoY 105.8%30.8%86.5%23.6%12.6%···
Revenue CAGR 3Y 71.2%44.5%37.4%·····
Revenue CAGR 5Y 47.5%·······
Valuation (TTM) 14
Metric Trend 20252024202320222021202020192018
Revenue TTM $73M$35M$27M$14M$12M$10M$14M·
Net Income TTM $-219M$-169M$-181M$-113M$-67M$-51M$-31M·
Market Cap $491M$967M$767M$884M$1.80B$379M$170M·
Enterprise Value ··$271M$575M$1.39B$393M··
P/E -2.2-4.8-3.6-7.8-22.8-6.7-3.4·
P/S 6.827.428.461.1153.936.412.3·
P/B 0.81.22.13.35.24.01.8·
P / Tangible Book 0.81.22.13.35.24.0··
P / Cash Flow -2.0-5.9-12.7-10.3-121.7-21.3-5.9·
P / FCF -1.9-5.8-12.1-8.4-107.0-19.9-5.6·
EV / EBITDA ··-1.5-5.1-21.7-7.8··
EV / FCF ··-4.3-5.5-82.7-20.7··
EV / Revenue ··10.139.8119.037.8··
Earnings Yield -44.6%-20.7%-28.1%-12.8%-4.4%-14.8%-29.4%·

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $73M $35M $27M $14M $12M
Operating Margin % -340.4% -595.0% -704.1% -806.6% -561.0%
Net Income $-219M $-169M $-181M $-113M $-67M
Diluted EPS $-3.16 $-2.90 $-5.08 $-3.80 $-2.67

Institutional owners (13F) 114 filers · $150.5M total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 114
Value held $150.5M
New positions 22
Exited positions 12
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
22 (+6 vs prior Q) 12 (-13 vs prior Q) 37 (-8 vs prior Q) 19 (+2 vs prior Q) -102K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
BAKER BROS. ADVISORS LP $46,153,914 10,885,357 30.67% Shares
FCPM III SERVICES B.V. $14,706,143 3,468,430 9.77% Shares
ARMISTICE CAPITAL, LLC $14,407,520 3,398,000 9.57% Shares
Long Focus Capital Management, LLC $14,037,313 3,310,687 9.33% Shares
RENAISSANCE TECHNOLOGIES LLC $6,501,616 1,533,400 4.32% Shares
GSK plc $6,485,339 1,529,561 4.31% Shares
MARSHALL WACE, LLP $3,383,266 797,940 2.25% Shares
Qube Research & Technologies Ltd $3,288,404 775,567 2.19% Shares
MORGAN STANLEY $2,829,221 667,269 1.88% Shares
SCHRODER INVESTMENT MANAGEMENT GROUP $2,555,707 615,833 1.70% Shares
CITADEL ADVISORS LLC $2,349,914 554,225 1.56% Shares
MILLENNIUM MANAGEMENT LLC $2,348,820 553,967 1.56% Shares
Peapod Lane Capital LLC $2,281,027 537,978 1.52% Shares
DIADEMA PARTNERS LP $1,961,950 462,724 1.30% Shares
TWO SIGMA INVESTMENTS, LP $1,842,606 434,577 1.22% Shares
JANE STREET GROUP, LLC $1,662,771 392,163 1.10% Shares
Aquilo Capital Management, LLC $1,457,691 171,695 0.97% Shares
Birchview Capital, LP $1,329,732 313,616 0.88% Shares
BlackRock, Inc. $1,188,837 280,386 0.79% Shares
MOORE CAPITAL MANAGEMENT, LP $1,166,000 275,000 0.77% Shares
Rangeley Capital, LLC $1,074,840 253,500 0.71% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $1,042,616 245,900 0.69% Put option
TWO SIGMA ADVISERS, LP $1,034,388 146,100 0.69% Shares
Palo Alto Investors LP $856,014 201,890 0.57% Shares
Sculptor Capital LP $839,113 197,904 0.56% Shares
Eversept Partners, LP $808,632 190,715 0.54% Shares
PINNACLE ASSOCIATES LTD $805,558 189,990 0.54% Shares
Cubist Systematic Strategies, LLC $800,393 103,410 0.53% Shares
FLAX POND CAPITAL, LLC $763,565 180,086 0.51% Shares
Jump Financial, LLC $708,504 167,100 0.47% Shares
Point72 Asset Management, L.P. $635,729 149,936 0.42% Shares
MANUFACTURERS LIFE INSURANCE COMPANY, THE $542,139 127,863 0.36% Shares
GOLDMAN SACHS GROUP INC $514,231 121,281 0.34% Shares
Persistent Asset Partners Ltd $497,157 117,254 0.33% Shares
XTX Topco Ltd $465,556 109,801 0.31% Shares
Quadrature Capital Ltd $441,350 104,092 0.29% Shares
TD Asset Management Inc $390,046 91,992 0.26% Shares
Virtus Investment Advisers, LLC $342,545 80,789 0.23% Shares
NANO CAP NEW MILLENNIUM GROWTH FUND L P $339,200 80,000 0.23% Shares
EntryPoint Capital, LLC $329,630 77,743 0.22% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $315,880 74,500 0.21% Call option
Marquette Asset Management, LLC $308,901 72,854 0.21% Shares
DAFNA Capital Management LLC $273,446 64,492 0.18% Shares
State of Tennessee, Department of Treasury $259,289 61,153 0.17% Shares
CITADEL ADVISORS LLC $238,288 56,200 0.16% Put option
SEI INVESTMENTS CO $223,804 52,784 0.15% Shares
ALPS ADVISORS INC $216,757 51,122 0.14% Shares
Verdad Advisers, LP $216,664 51,100 0.14% Shares
ADAR1 Capital Management, LLC $214,705 50,638 0.14% Shares
JANE STREET GROUP, LLC $151,792 35,800 0.10% Call option

Show all 114 institutional owners →

Activists & 5%+ owners 7 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×3 filings Dec. 17, 2024 · Initial filing · SEC
GSK plc July 20, 2023 · Initial filing · SEC
Tybourne Capital Management (HK) Limited, Tybourne Capital Management Limited, Tybourne Kesari Limited, Viswanathan Krishnan, Aquila Investments IV ×4 filings March 14, 2022 · Initial filing · SEC
GlaxoSmithKline plc ×5 filings Sept. 16, 2021 · Initial filing · SEC
SVLSF V, LLC, SV Life Sciences Fund V, L.P., SV Life Sciences Fund V Strategic Partners, L.P., SV Life Sciences Fund V (GP), L.P. ×2 filings Aug. 16, 2021 · Initial filing · SEC
Vertex Venture Holdings Ltd., Vertex Global HC Fund I Pte. Ltd., Vertex Venture Management Pte. Ltd. ×2 filings Jan. 20, 2021 · Initial filing Passive investment SEC
Cambridge Innovation Capital (Jersey) Limited June 7, 2019 · Initial filing Passive investment SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 32 insiders · 14 officers · 16 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Kevin Lee CHIEF EXECUTIVE OFFICER July 6, 2026 S 603,671 0 8 $-258,045
Travis Alvin Thompson Chief Financial Officer July 15, 2026 A 64,441 0 8 $-27,253
Alethia Young Chief Financial Officer Jan. 2, 2026 A 87,081 0 5 $-54,590
Lee Kalowski President and CFO April 3, 2023 S 30,309 0 0 $0
Jennifer Scott Perry Chief Operating Officer July 15, 2026 A 91,052 0 6 $-13,016
Alistair Milnes CHIEF OPERATING OFFICER Jan. 2, 2026 A 136,717 0 4 $-61,986
Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF July 15, 2026 A 94,375 0 8 $-56,832
Michael Skynner CHIEF SCIENTIFIC OFFICER July 15, 2026 A 157,171 0 8 $-79,059
Eric Westin Chief Medical Officer March 25, 2025 A · 0 0 $0
Nigel Crockett CHIEF BUSINESS OFFICER Jan. 2, 2025 A 51,053 0 0 $0
Santiago Arroyo CHIEF DEVELOPMENT OFFICER Jan. 2, 2025 A 69,057 0 0 $0
Nicholas Keen CHIEF SCIENTIFIC OFFICER July 3, 2024 S 62,024 0 0 $0
Dominic Smethurst Chief Medical Officer Jan. 3, 2023 A 36,699 0 0 $0
Peter Brian Leone Chief Business Officer May 28, 2019 A · 0 0 $0
Robert Charles Swanton Director Jan. 2, 2026 A 19,213 0 1 $-872
Stephen H. Sands Director Jan. 2, 2026 A 26,893 0 0 $0
Alessandro Riva Director Jan. 2, 2026 A 19,880 0 0 $0
Janice Bourque Director Jan. 2, 2026 A 32,500 0 0 $0
Gregory Paul Winter Director Jan. 2, 2026 A 196,427 0 0 $0
Roger D Dansey Director Jan. 2, 2026 A 15,532 0 0 $0
Jose-Carlos Gutierrez-Ramos Director Jan. 2, 2026 A 32,500 0 0 $0
Herve Hoppenot Director Jan. 2, 2026 A 15,532 0 0 $0
Pierre Legault Director Jan. 2, 2025 A 46,000 0 0 $0
Richard N Kender Director Jan. 2, 2025 A 23,000 0 0 $0
Veronica Gh Jordan Director Jan. 2, 2024 A 16,750 0 0 $0
Kate Bingham Director July 14, 2021 S 38,708 0 0 $0
Carolyn Ng Director May 28, 2019 C 1,427,151 0 0 $0
Deborah Harland Director May 28, 2019 C 1,915,275 0 0 $0
Michael Anstey Director May 28, 2019 C 1,751,437 0 0 $0
Cambridge Innovation Capital (Jersey) Ltd 10% owner May 28, 2019 C 1,751,437 0 0 $0
Vertex Global Healthcare Fund I Pte Ltd. 10% owner May 28, 2019 C 1,621,168 0 0 $0
GSK plc · July 15, 2020 S 1,910,531 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 4 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
BBC · ETFis Series Trust I 0.64% 76,743 NS July 31, 2026 N-PORT
QQQS · Invesco Exchange-Traded Fund Trust … 0.45% 29,023 SH Oct. 2, 2026 Daily
IBBQ · Invesco Exchange-Traded Fund Trust … 0.01% 3,286 SH Oct. 2, 2026 Daily
IBB · iShares Trust 0.01% 281,381 SH Sept. 11, 2026 Daily

BCYC Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 16 analysts BUY
Median target $9.50 +181.1%
5 31.2% Strong Buy
7 43.8% Buy
4 25.0% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

6 analysts · 2026-09-28

Mean target $9.50 +181.1%

← Below all targets Current price $3.38
Low$5.00 Mean$9.50 High$14.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
BCYC $491M -2.2 105.8% -301.7% -34.2% ·
AUTL · -1.8 644.9% -381.4% -109.6% ·
TLSA · -9.3 · · -924.3% ·
OKYO · -6.7 · · -263.8% ·
ROIV $19.95B -51.3 -71.6% -3629.2% -6.5% ·

Latest News Recent headlines mentioning this company

23

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Jul 30, 2026